Who
Martin D. Madaus
Interim CEO
Company insider
Files Form 4 as: Interim CEO, Azenta; Director, Haemonetics; Director, Repligen; Director, Hologic; Director, Quanterix; Director, Standard BioTools; Director, Mettler-Toledo International; Director, Covidien.
In numbers
- Trades disclosed
- 336
- Buys
- 11
- Sells
- 53
- Bought
- $2.1M
- Sold
- $5.2M
- Companies
- 9
- Companies where not an officer
- 7
- First trade
- 15 Feb 2006
- Last trade
- 22 Sep 2026
- Last filed
- 23 Sep 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 22 Sep 2026filed 23 Sep 2026 | AZTA AzentaSemiconductor Equipment | SEC FORM 4 Code F | $50K1,456 at $34.28 | filing |
| 22 Sep 2026filed 23 Sep 2026 | AZTA AzentaSemiconductor Equipment | SEC FORM 4 Code F | $50K1,456 at $34.28 | filing |
| 14 Sep 2026filed 16 Sep 2026 | AZTA AzentaSemiconductor Equipment | SEC FORM 4 Code A | —36,653 at $0.00 | filing |
| 14 Sep 2026filed 16 Sep 2026 | AZTA AzentaSemiconductor Equipment | SEC FORM 4 Code A | —36,653 at $0.00 | filing |
| 24 Jul 2026filed 28 Jul 2026 | HAE HaemoneticsMedical Devices | SEC FORM 4 Code A | —2,538 | filing |
| 24 Jul 2026filed 28 Jul 2026 | HAE HaemoneticsMedical Devices | SEC FORM 4 Code A | —2,538 | filing |
| 14 May 2026filed 18 May 2026 | RGEN RepligenBiotechnology | SEC FORM 4 Code A | —995 at $0.00 | filing |
| 14 May 2026filed 18 May 2026 | RGEN Repligenoption or derivative · Biotechnology | SEC FORM 4 Code A | —2,239 at $0.00 | filing |
| 14 May 2026filed 18 May 2026 | RGEN Repligenoption or derivative · Biotechnology | SEC FORM 4 Code A | —2,239 at $0.00 | filing |
| 14 May 2026filed 18 May 2026 | RGEN RepligenBiotechnology | SEC FORM 4 Code A | —995 at $0.00 | filing |
| 7 Apr 2026filed 9 Apr 2026 | HologicMedical Devices | SEC FORM 4 Code D | —5,396 | filing |
| 7 Apr 2026filed 9 Apr 2026 | HologicMedical Devices | SEC FORM 4 Code D | —5,445 | filing |
| 7 Apr 2026filed 9 Apr 2026 | Hologicoption or derivative · Medical Devices | SEC FORM 4 Code D | —1,016 | filing |
| 7 Apr 2026filed 9 Apr 2026 | Hologicoption or derivative | SEC FORM 4 Code D | —1,016 | filing |
| 7 Apr 2026filed 9 Apr 2026 | Hologicoption or derivative | SEC FORM 4 Code D | —5,535 | filing |
| 7 Apr 2026filed 9 Apr 2026 | Hologicoption or derivative · Medical Devices | SEC FORM 4 Code D | —5,535 | filing |
| 7 Apr 2026filed 9 Apr 2026 | Hologic | SEC FORM 4 Code D | —5,396 | filing |
| 7 Apr 2026filed 9 Apr 2026 | Hologic | SEC FORM 4 Code D | —5,445 | filing |
| 26 Feb 2026filed 2 Mar 2026 | HologicMedical Devices | SEC FORM 4 Code A | —3,190 | filing |
| 26 Feb 2026filed 2 Mar 2026 | Hologic | SEC FORM 4 Code A | —3,190 | filing |
News
Twist Bioscience (NASDAQ:TWST) versus Quanterix (NASDAQ:QTRX) Financial AnalysisQTRX · tickerreport.com · 15 Oct 2026Analyzing Qiagen (NYSE:QGEN) & Mettler-Toledo International (NYSE:MTD)MTD · tickerreport.com · 14 Oct 2026
0 headlines in the last 90 days name Martin D. Madaus; 2 articles from the last 14 days about the 4 companies they traded most, at most three about any one of them.